On September 22 to 24, 2016, the fifth China rare disease summit forum, jointly hosted by the center of rare diseases development(CORD) and Shulan Medical, was solemnly opened in Hangzhou. The summit forum was initiated by the center of rare diseases development (CORD) in 2012 and has successfully held four sessions. It is currently the largest comprehensive forum in the field of rare diseases in China. This summit forum invited experts from the US FDA and NIH, Australia, Japan, Taiwan, Hong Kong and other countries and regions to come together to discuss the development of China's rare disease cause from different levels such as diagnosis and treatment technology, orphan drugs, and policies. Dr. Lu Xianping, the president and chief scientific officer of CHIPSCREEN BIOSCIENCES, was invited to attend and make a keynote speech.

The president of the conference, Mr. Zheng Shusen, an academician of the Chinese Academy of Engineering, delivered an opening address to the conference. Dr. Lu Xianping gave a thematic report on " research and development and challenges of Chidamide, China's first drug listed as orphan drug" at the forum on " orphan drug research and development and market access". He introduced the 12-year research and development process and future challenges of Chidamide, China's first self-developed orphan drug for treating peripheral T-cell lymphoma, to the participants, which was excellent and won applause from the participants.

The conference attracted experts and scholars from different fields such as the government, the medical industry, pharmaceutical enterprises and foundations, as well as representatives of organizations of sick people, patients and their families, social loving people and the media to attend. This congress has strengthened the exchange and cooperation between relevant parties, provided a platform for the presentation and collision of authoritative views of industry experts, is a high-quality national academic gathering in the field of rare diseases in the country, and will certainly play a more active role in promoting the work of rare diseases in China.